265 related articles for article (PubMed ID: 27641330)
1. Translational research in neuroendocrine tumors: pitfalls and opportunities.
Capdevila J; Casanovas O; Salazar R; Castellano D; Segura A; Fuster P; Aller J; García-Carbonero R; Jimenez-Fonseca P; Grande E; Castaño JP
Oncogene; 2017 Apr; 36(14):1899-1907. PubMed ID: 27641330
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic neuroendocrine tumors: a review.
Young K; Iyer R; Morganstein D; Chau I; Cunningham D; Starling N
Future Oncol; 2015; 11(5):853-64. PubMed ID: 25757686
[TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
4. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies.
Auernhammer CJ; Spitzweg C; Angele MK; Boeck S; Grossman A; Nölting S; Ilhan H; Knösel T; Mayerle J; Reincke M; Bartenstein P
Lancet Diabetes Endocrinol; 2018 May; 6(5):404-415. PubMed ID: 29229497
[TBL] [Abstract][Full Text] [Related]
5. Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors.
Dromain C; Pavel M; Ronot M; Schaefer N; Mandair D; Gueguen D; Cheng C; Dehaene O; Schutte K; Cahané D; Jégou S; Balazard F
Future Oncol; 2023 Oct; 19(32):2171-2183. PubMed ID: 37497626
[TBL] [Abstract][Full Text] [Related]
6. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.
Sundin A; Rockall A
Neuroendocrinology; 2012; 96(4):261-71. PubMed ID: 22907438
[TBL] [Abstract][Full Text] [Related]
8. An update on gastroenteropancreatic neuroendocrine tumors.
Cives M; Strosberg J
Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
[TBL] [Abstract][Full Text] [Related]
9. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
Garcia-Carbonero R; Garcia-Figueiras R; Carmona-Bayonas A; Sevilla I; Teule A; Quindos M; Grande E; Capdevila J; Aller J; Arbizu J; Jimenez-Fonseca P;
Cancer Metastasis Rev; 2015 Dec; 34(4):823-42. PubMed ID: 26433592
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic neuroendocrine tumors: a comprehensive review.
Zhou C; Zhang J; Zheng Y; Zhu Z
Int J Cancer; 2012 Sep; 131(5):1013-22. PubMed ID: 22437917
[TBL] [Abstract][Full Text] [Related]
11. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
12. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
Halperin DM; Kulke MH; Yao JC
Annu Rev Med; 2015; 66():1-16. PubMed ID: 25341008
[TBL] [Abstract][Full Text] [Related]
13. Gastroenteropancreatic endocrine tumors.
Meeker A; Heaphy C
Mol Cell Endocrinol; 2014 Apr; 386(1-2):101-20. PubMed ID: 23906538
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
[TBL] [Abstract][Full Text] [Related]
15. Hegemony and cost-effectiveness of endoscopic ultrasound (EUS) in the field of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs).
De Angelis C; Manfrè SF; Bruno M; Pellicano R
Minerva Med; 2014 Oct; 105(5):363-70. PubMed ID: 25325565
[TBL] [Abstract][Full Text] [Related]
16. Cases in the Management of GEP-NETs: The Use of Surgery, an Underutilized Option in the Management of Advanced-Stage NETs.
Boudreaux JP
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):7-11. PubMed ID: 27167992
[No Abstract] [Full Text] [Related]
17. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.
de Mestier L; Dromain C; d'Assignies G; Scoazec JY; Lassau N; Lebtahi R; Brixi H; Mitry E; Guimbaud R; Courbon F; d'Herbomez M; Cadiot G
Endocr Relat Cancer; 2014 Jun; 21(3):R105-20. PubMed ID: 24351682
[TBL] [Abstract][Full Text] [Related]
18. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
19. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).
Orgera G; Krokidis M; Cappucci M; Gourtsoyianni S; Tipaldi MA; Hatzidakis A; Rebonato A; Rossi M
Cardiovasc Intervent Radiol; 2015 Feb; 38(1):13-24. PubMed ID: 25366087
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]